Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach

Future Virology

Volumn 4, Issue 2, 2009, Pages 155-164

  Gerna, Giuseppe ^a   Baldanti, Fausto ^a   Lilleri, Danielle ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

HCMV; Hematopoietic stem cell transplant recipients; Pre emptive therapy; Prophylaxis; Solid organ transplant recipients

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; VIRUS ISOLATION;

HUMAN HERPESVIRUS 5;

EID: 70349219922     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.2.155     Document Type: Review

References (53)

1. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl. J. Med. 338, 1741-1751 (1998).
2. Boeckh M, Ljungman P: Cytomegalovirus infection after bone marrow transplantation. In: Transplant infections. Paya C (Ed.). Lippincot-Raven Philadelphia, PA, USA 215-227 (1998).
3. Ljungman P, Griffiths P, Paya C: Definitions of HCMV infection and disease in transplant recipients. Clin. Infect. Dis. 34, 1094-1097 (2002).
4. Gerna G, Baldanti F, Grossi P et al.: Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. Rev. Med. Microbiol. 12, 155-175 (2001).
5. Razonable RR, Paya CV, Smith TF: Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid organ transplant recipients. J. Clin. Microbiol. 40, 746-752 (2002).
6. Grossi P, Minoli L, Percivalle E, Irish W, Viganò M, Gerna G: Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 59, 847-851 (1995).
7. Gerna G, Percivalle E, Baldanti F, et al.: Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J. Virol. 74, 5629-5638 (2000).
8. Gerna G, Sarasini A, Lilleri D et al.: In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J. Infect. Dis. 188, 1639-1647 (2003).
9. Gerna G, Lilleri D, Zecca M et al.: Rising antigeriemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 90, 526-533 (2005).
10. Cortez KJ, Fischer SH, Fahle GA et al.: Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J. Infect. Dis. 188, 967-972 (2003).
11. Mengelle C, Sandres-Saune K, Pasquier C et al.: Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J. Clin. Microbiol. 41, 3840-3845 (2003).
12. Razonable RR, van Cruijsen H, Brown RA et al.: Dynamics of cytomegalovirus replication during pre-emptive therapy with oral ganciclovir. J. Infect. Dis. 187, 1801-1808 (2003).
13. Gerna G, Baldanti F, Lilleri D et al.: Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 75, 1012-1019 (2003).
14. Gerna G, Lilleri D, Baldanti F et al.: Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 101, 5053-5060 (2003).
15. Gerna G, Baldanti F, Torsellini M et al.: Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cut-off for guiding pre-emptive therapy in transplant recipients: a randomized study. Antivir. Ther. 12, 63-72 (2007).
16. Lilleri D, Gerna G, Furione M et al.: Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving hematopoietic stem cell transplantation as compared with qualitative pp65-antigenemia. Blood 110, 2757-2760 (2007).
17. Gerna G, Lilleri D, Caldera D et al.: Validation of a DNAemia cut-off for pre-emptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 41, 873-879 (2008).
18. Gerna G, Vitulo P, Rovida F et al.: Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung-transplant recipients. J. Med. Virol. 78, 408-416 (2006); erratum in J. Med. Virol. 80, 1869 (2008).
19. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC: Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis. 190, 1076-1083 (2004).
20. Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ: Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79, 381-386 (2005).
21. Gratama JW, van Esser JW, Lamers CH et al.: Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8' T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98, 1358-1364 (2001).
22. Cwynarski K, Ainsworth J, Cobbold M et al.: Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97, 1232-1240 (2001).
23. Kern F, Faulhaber N, Frommel C et al.: Analysis of CD8 T-cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30, 1676-1682 (2000).
24. + T cells. Blood 100, 3690-3697 (2002).
25. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108, 14063-1412 (2006).
26. Gerna G, Lilleri D, Fornara C et al.: Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6, 2356-2364 (2006).
27. Limaye AP, Bakthavatsalam R, Kim HW et al.: Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81, 1645-1652 (2006).
28. Limaye AP, Bakthavatsalam R, Kim HW et al.: Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78, 1390-1396 (2004).
29. Kijpittayarit-Arthurs S, Eid AJ, Kremers W et al.: Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J. Heart Lung Transplant. 26, 1019-1024 (2007).
30. Hakki M, Riddell SR, Storek J et al.: Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102, 3060-3067 (2003).
31. Kusne S, Grossi P, Irish W et al.: Cytomegalovirus pp65 antigenemia monitoring as a guide for pre-emptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 68, 1125-1131 (1999).
32. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV: Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis-C virus sequelae, and mortality) in liver-transplant recipients with the use of pre-emptive therapy for 13 years. Transplantation 79, 1428-1434 (2005).
33. Singh N: Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J. Clin. Virol. 35, 474-477 (2006).
34. Singh N: Antiviral drugs for cytomegalovirus in transplant recipients: advantages of pre-emptive therapy. Rev. Med. Virol. 16, 281-287 (2006).
35. Khoury JA, Storch GA, Bohl DL et al.: Prophylactic versus pre-emptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6, 2134-2143 (2006).
36. Diaz-Pedroche C, Lumbreras C, Del Valle P et al.: Efficacy and safety of valgancyclovir as pre-emptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant. Proc. 37, 3766-3767 (2005).
37. Diaz-Pedroche C, Lumbreras C, San Juan R et al.: Valganciclovir pre-emptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid organ transplant recipients. Transplantation 82, 30-35 (2006).
38. Lopau K, Greser A, Wanner C: Efficacy and safety of pre-emptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin. Transplant. 21, 80-85 (2007).
39. Mattes FM, Hainsworth EG, Geretti AM et al.: A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for pre-emptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis. 189, 1355-1361 (2004).
40. Reusser P, Einsele H, Lee J et al.: Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99, 1159-1164 (2002).
41. Ayala E, Greene J, Sandin R et al.: Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Tramplant. 37, 851-856 (2006).
42. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF: Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 37, 693-698 (2006).
43. Winston DJ, Baden LR, Gabriel DA et al.: Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol. Blood Marrow Transplant. 12, 635-640 (2006).
44. Einsele H, Reusser P, Bornhauser M et al.: Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107, 3002-3008 (2006).
45. Busca A, de Fabridis P, Ghisetti V et al.: Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl. Infect. Dis. 9, 102-107 (2007).
46. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R: Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 37, 51-56 (2006).
47. Machado CM, Dulley FL, Boas LS et al.: CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 26, 413-417 (2000).
48. Babel N, Gabdrakhmanova L, Juergensen JS et al.: Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients a single center experience. Transplantation 78, 283-285 (2004).
49. Humor A, Siegal D, Moussa G, Kumar D: A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J. Infect. Dis. 192, 1154-1157 (2005).
50. Luan FL, Chopra P, Park J, Nofman S, Cibrik D, Ojo A: Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. Transplant. Proc. 38, 3673-3675 (2006).
51. Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7, 2106-2113 (2007).
52. Baldanti F, Lurain N, Gerna G: Clinical and biological aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 65, 403-409 (2004).
53. Baldanti F, Lilleri D, Gerna G: Monitoring of human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237-241 (2008).